特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
363132

カテプシンS:パイプライン製品の分析

Cathepsin S - Pipeline Review, H2 2020

出版日: | 発行: Global Markets Direct | ページ情報: 英文 29 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.15円
カテプシンS:パイプライン製品の分析
出版日: 2020年10月30日
発行: Global Markets Direct
ページ情報: 英文 29 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、カテプシンS薬剤の開発状況関する情報を提供しており、開発段階、薬剤標的、作用機序、投与経路および分子タイプ別の分析、治療薬の開発に従事している企業の概要、最新ニュースやプレスリリースなどの情報をお届けします。

イントロダクション

  • 調査範囲

カテプシンSの概要

治療薬の開発

カテプシンS:開発中の製品 - 開発段階別

カテプシンS:開発中の製品 - 治療範囲別

カテプシンS:開発中の製品 - 適応症別

カテプシンS:パイプライン製品の概況

  • 後期段階の製品
  • 初期段階の製品

カテプシンS:企業で開発中の製品

カテプシンS:治療薬の評価

  • 単剤療法/併用療法製品別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

カテプシンSの治療薬開発に従事している企業

  • Amura Holdings Limited
  • F. Hoffmann-La Roche Ltd.
  • Fusion Antibodies Limited
  • LEO Pharma A/S
  • Virobay Inc.

カテプシンS:薬剤プロファイル

カテプシンS:休止中のプロジェクト

カテプシンS:開発が中止された製品

カテプシンS:主なニュースとプレスリリース

付録

図表

List of Tables

List of Tables

  • Number of Products under Development by Stage of Development, H2 2020
  • Number of Products under Development by Therapy Areas, H2 2020
  • Number of Products under Development by Indication, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020
  • Number of Products under Investigation by Universities/Institutes, H2 2020
  • Products under Investigation by Universities/Institutes, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Pipeline by F. Hoffmann-La Roche Ltd, H2 2020
  • Pipeline by Virobay Inc, H2 2020
  • Dormant Products, H2 2020
  • Dormant Products, H2 2020 (Contd..1), H2 2020
  • Discontinued Products, H2 2020

List of Figures

List of Figures

  • Number of Products under Development by Stage of Development, H2 2020
  • Number of Products under Development by Therapy Areas, H2 2020
  • Number of Products under Development by Top 10 Indications, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
目次
Product Code: GMDHC2683TDB

Summary:

According to the recently published report 'Cathepsin S - Pipeline Review, H2 2020'; Cathepsin S (CTSS or EC 3.4.22.27) pipeline Target constitutes close to 5 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes.

Cathepsin S (CTSS or EC 3.4.22.27) - Cathepsin S is a lysosomal enzyme that belongs to the papain family of cysteine proteases. Cathepsin S has a role in itch and pain, or nociception. The nociceptive activity results from cathepsin S functioning as a signaling molecule via activation of protease-activated receptors 2 and 4 members of the G-protein coupled receptor family. Cathepsin S has a physiological role outside the lysosome. Immune cells, including macrophages and microglia, secrete cathepsin S in response to inflammatory mediators including lipopolysaccharides, proinflammatory cytokines and neutrophils.

The report 'Cathepsin S - Pipeline Review, H2 2020' outlays comprehensive information on the Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase 0 and Preclinical stages are 1 and 3 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Oncology, Gastrointestinal, Immunology and Metabolic Disorders which include indications Alzheimer's Disease, Autoimmune Disorders, Cancer Pain, Diabetic Retinopathy, Liver Fibrosis, Neuropathic Pain (Neuralgia), Pancreatic Cancer and Primary Biliary Cholangitis (Primary Biliary Cirrhosis).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Cathepsin S (CTSS or EC 3.4.22.27)
  • The report reviews Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Cathepsin S (CTSS or EC 3.4.22.27)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cathepsin S (CTSS or EC 3.4.22.27) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Cathepsin S (CTSS or EC 3.4.22.27) - Overview
  • Cathepsin S (CTSS or EC 3.4.22.27) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Cathepsin S (CTSS or EC 3.4.22.27) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Cathepsin S (CTSS or EC 3.4.22.27) - Companies Involved in Therapeutics Development
  • F. Hoffmann-La Roche Ltd
  • Virobay Inc
  • Cathepsin S (CTSS or EC 3.4.22.27) - Drug Profiles
  • RO-5461111 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit Cathepsin S for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VBY-285 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VBY-50365 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VBY-825 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Cathepsin S (CTSS or EC 3.4.22.27) - Dormant Products
  • Cathepsin S (CTSS or EC 3.4.22.27) - Discontinued Products
  • Cathepsin S (CTSS or EC 3.4.22.27) - Product Development Milestones
  • Featured News & Press Releases
  • Nov 14, 2014: Virobay To Present Data On Two Cathepsin S Inhibitor Programs In Neuropathic Pain And Alzheimer's Disease At The 2014 Society For Neuroscience Annual Meeting
  • Nov 14, 2011: Virobay's Spectrum-Selective Cathepsin Inhibitor Shows Efficacy In Bone Cancer Model
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.